可溶性CD163和可溶性甘露糖受体预测肝硬化患者生存与失代偿,并与肠道通透性和细菌易位相关
该研究前瞻性纳入101例肝硬化患者(Child-Pugh A级72例,B/C级29例)和31例健康对照,中位随访37个月。结果显示sCD163和sMR在肝硬化患者中显著升高并随疾病严重程度增加,sCD163>5.9 mg/L与36个月生存率降低相关,sMR>45.5 μg/dL与12个月内肝硬化并发症增多相关,且两者与肠道通透性和细菌易位标志物相关。
要点
- sCD163和sMR在肝硬化患者中显著升高,且随Child-Pugh分级加重而升高。
- sCD163>5.9 mg/L患者36个月生存率71% vs 98%(P<.001)。
- sMR>45.5 μg/dL患者12个月内肝硬化并发症发生率73% vs 9%(P<.001)。
核心结论
- sCD163可预测肝硬化患者长期生存,sMR可预测肝硬化相关并发症的发生。
- 肠道屏障功能障碍与巨噬细胞活化相关,提示两者之间存在联系。
研究设计与样本
- 前瞻性研究纳入101例肝硬化患者(Child-Pugh A级72例,B/C级29例)和31例健康对照,中位随访37个月。
主要发现
- sCD163中位血浆水平:健康对照1.3 mg/L,Child-Pugh A级4.2 mg/L,B/C级8.4 mg/L(P<.001)。
- sMR中位血浆水平:健康对照15.8 μg/dL,Child-Pugh A级36.5 μg/dL,B/C级66.3 μg/dL(P<.001)。
- 观察期间共21例患者死亡;sCD163>5.9 mg/L者36个月生存率71% vs 98%(P<.001)。
- sMR>45.5 μg/dL者12个月内肝硬化并发症发生率73% vs 9%(P<.001)。
- sCD163和sMR均与乳果糖-甘露醇比值、二胺氧化酶、脂多糖和白细胞介素-8相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Activated hepatic macrophages play a key role in inflammation and fibrosis progression in chronic liver disease. AIM: To assess the prognostic value of soluble (s)CD163 and mannose receptor (sMR) in cirrhotic patients and explore associations with markers of intestinal permeability (lactulose-mannitol ratio, diamine oxidase), bacterial translocation (endotoxin, lipopolysaccharide-binding protein) and markers of systemic immune activation (interleukin-6, interleukin-8, sCD14). METHODS: We prospectively investigated 101 cirrhotic patients (Child-Pugh class A: n = 72, Child-Pugh classes B and C: n = 29) and 31 healthy controls. Patients were observed for a median follow-up of 37 months. RESULTS: Median plasma levels of sCD163 and soluble mannose receptor were significantly elevated in cirrhotic patients (P < .001) and increased with disease severity (sCD163 in healthy controls = 1.3, Child-Pugh class A = 4.2, Child-Pugh classes B and C = 8.4 mg/L; sMR in healthy controls = 15.8, Child-Pugh class A = 36.5, Child-Pugh classes B and C = 66.3 μg/dL). A total of 21 patients died during the observation period. Patients with sCD163 levels above 5.9 mg/L showed significantly reduced survival (survival rate after 36 months: 71% versus 98%, P < .001). Patients with soluble mannose receptor levels above 45.5 μg/dL developed significantly more complications of cirrhosis within 12 months (73% versus 9%, P < .001). Furthermore, both variables correlated with the lactulose-mannitol ratio, diamine oxidase, lipopolysaccharide and interleukin-8. CONCLUSION: Our data demonstrate the prognostic value of sCD163 in predicting long-term survival in patients with liver cirrhosis and identify soluble mannose receptor as a prognostic marker for occurrence of cirrhosis-associated complications. The correlation between gut barrier dysfunction and activation of macrophages points towards a link between them.
引用
- Rainer F, Horvath A, Sandahl TD, et al. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. Aliment Pharmacol Ther. 2017. PMID: 29266346. doi:10.1111/apt.14474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。